Thera-SAbDab

EFALIZUMAB

>   Structural Summary
TherapeuticEfalizumab
TargetITGAL
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK
100% seqID Fv Structure3eo9 [Fvs: HL], 3eoa [Fvs: BA, HL], 3eob [Fvs: BA, HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental Technologyna
INN Year Proposed2001
INN Year Recommended2002
Companies InvolvedGenentech, Merck Serono, XOMA
Conditions ApprovedPsoriasis
Conditions Activena
Conditions DiscontinuedPsoriatic arthritis, Type 1 diabetes mellitus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]